Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22065039 | 0.94 | BTN3A1 (0.51) | BTN3A1ELANEPRTN3CARM1PRMT6 | |
| SCHEMBL22066280 | 0.91 | BTN3A1 (0.47) | BTN3A1ELANEPRTN3CARM1PRMT6 | |
| SCHEMBL22065043 | 0.90 | BTN3A1 (0.47) | BTN3A1ELANEPRTN3CARM1PRMT6 | |
| SCHEMBL20833694 | 0.89 | BTN3A1 (0.43) | BTN3A1ELANEPRTN3CASP1ALDH1A1 | |
| SCHEMBL18973564 | 0.89 | BTN3A1 (0.55) | BTN3A1ELANEPRTN3KLK1 | |
| SCHEMBL22065164 | 0.89 | BTN3A1 (0.40) | BTN3A1ELANEPRTN3CASP1ALDH1A1 | |
| SCHEMBL22065159 | 0.88 | BTN3A1 (0.45) | BTN3A1ELANEPRTN3CARM1PRMT6 | |
| SCHEMBL22065165 | 0.87 | BTN3A1 (0.42) | BTN3A1ELANEPRTN3CASP1ALDH1A1 | |
| SCHEMBL22065801 | 0.87 | BTN3A1 (0.42) | BTN3A1ELANEPRTN3CASP1ALDH1A1 | |
| SCHEMBL22065648 | 0.87 | BTN3A1 (0.39) | BTN3A1ELANEPRTN3CASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PPA1, PPIP5K2, TYMP | BTN3A1 4531/4885ELANE 4653/4885PRTN3 1013/4885 |
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PNP, NTPCR, TYMP | BTN3A1 2948/4885ELANE 3870/4885PRTN3 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.